Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.57 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | GSK3B | P49841 | 1/20 | 0.55 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.53 |
| ▸ | RELA | Q04206 | 1/20 | 0.53 |
| ▸ | F3 | P13726 | 2/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.53 |
| ▸ | ESR1 | P03372 | 2/20 | 0.52 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6233317 | 1.00 | ALDH1A1 (0.57) | ALDH1A1CYP3A4CYP2A6MAPTKDM4E | |
| SCHEMBL49339 | 1.00 | ALDH1A1 (0.57) | ALDH1A1CYP3A4CYP2A6MAPTKDM4E | |
| SCHEMBL23209621 | 0.98 | ALDH1A1 (0.56) | ALDH1A1CYP3A4CYP2A6MAPTKDM4E | |
| SCHEMBL9320106 | 0.80 | CYP1A1 (0.61) | MAPTKDM4EHDAC6ESR1TUBB1 | |
| SCHEMBL9320099 | 0.80 | CYP1A1 (0.61) | MAPTKDM4EHDAC6ESR1TUBB1 | |
| SCHEMBL9322786 | 0.78 | RELA (0.59) | RELATUBB1CYP1A2CYP1A1CYP19A1 | |
| SCHEMBL9322769 | 0.78 | RELA (0.59) | RELATUBB1CYP1A2CYP1A1CYP19A1 | |
| SCHEMBL9320085 | 0.78 | MAPT (0.60) | ALDH1A1CYP3A4MAPTKDM4ELMNA | |
| SCHEMBL9320094 | 0.78 | MAPT (0.60) | ALDH1A1CYP3A4MAPTKDM4ELMNA | |
| SCHEMBL13790336 | 0.78 | RELA (0.81) | ALDH1A1CYP3A4MAPTKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2876 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240241139-A1 | DIAGNOSIS OF AUTISM SPECTRUM DISORDER BY MULTIOMICS PLATFORM | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-07-18 | — | — | US | claimed |
| EP-4374848-A1 | ANTIBIOTIC PHARMACEUTICAL COMPOSITION CAPABLE OF SUBCUTANEOUS ADMINISTRATION | Shanghai Bao Pharmaceuticals Co., Ltd. (CN) | 2024-05-29 | — | — | EP | claimed |
| EP-4355766-A1 | GENE THERAPY FOR TUBEROUS SCLEROSIS | Bridgebio Gene Therapy Research, Inc. (US) | 2024-04-24 | — | — | EP | claimed |
| US-11958887-B2 | Gene therapy for tuberous sclerosis | THE GENERAL HOSPITAL CORPORATION (US) | 2024-04-16 | — | — | US | claimed |
| EP-4348265-A2 | DIAGNOSIS OF AUTISM SPECTRUM DISORDER BY MULTIOMICS PLATFORM | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2024-04-10 | — | — | EP | claimed |
| US-20240025984-A1 | CYTOSOLIC PROTEIN TARGETING DEUBIQUITINASES AND METHODS OF USE | FLUX THERAPEUTICS, INC. | 2024-01-25 | — | — | US | claimed |
| US-20240002473-A1 | MEMBRANE PROTEIN TARGETING ENGINEERED DEUBIQUITINASES AND METHODS OF USE THEREOF | FLUX THERAPEUTICS, INC. | 2024-01-04 | — | — | US | claimed |
| CN-116806223-A | Engineered deubiquitinase targeting cytoplasmic proteins and methods of use thereof | 弗勒克斯治疗股份有限公司 | 2023-09-26 | — | — | CN | claimed |
| CN-116802198-A | Engineered deubiquitinase targeting membrane proteins and methods of use thereof | 弗勒克斯治疗股份有限公司 | 2023-09-22 | — | — | CN | claimed |
| EP-4240754-A1 | MEMBRANE PROTEIN TARGETING ENGINEERED DEUBIQUITINASES AND METHODS OF USE THEREOF | Flux Therapeutics, Inc. (US) | 2023-09-13 | — | — | EP | claimed |
| EP-0792371-A1 | COMBINATION METHOD FOR ACNE TREATMENT | Merck & Co., Inc. (US) | 1997-09-03 | — | — | EP | claimed |
| EP-0786999-A1 | COMBINATION METHOD FOR ACNE TREATMENT | Merck & Co., Inc. (US) | 1997-08-06 | — | — | EP | claimed |
| WO-1997009973-A2 | PERIPHERALLY ACTIVE ANTI-HYPERALGESIC OPIATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1997-03-20 | — | — | WO | claimed |
| EP-0759750-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO, Howard, K. (US) | 1997-03-05 | — | — | EP | claimed |
| EP-0733110-A1 | TUBEROUS SCLEROSIS 2 GENE AND USES THEREOF | University of Wales College of Medicine (GB) | 1996-09-25 | — | — | EP | claimed |
| US-5543417-A | 5 Alpha-reductase inhibitor and at least one of an antibacterial agent, a keratolytic agent or an anti-inflammatory agent | MERCK & CO., INC. (US) | 1996-08-06 | — | — | US | claimed |
| WO-1996012487-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | claimed |
| WO-1996012817-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | claimed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | claimed |
| WO-1995018226-A1 | TUBEROUS SCLEROSIS 2 GENE AND USES THEREOF | UNIVERSITY OF WALES COLLEGE OF MEDICINE (GB) | 1995-07-06 | — | — | WO | claimed |